S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval
Send us Fan Mail Last Thursday, March 14, Rezdiffra (resmetirom) became the first MASH drug approved in the US. A global panel of Key Opinion Leaders convenes to discuss their excitement about this ap...
16 Mar 20241h 4min
S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT
Send us Fan Mail This conversation comes from our first look at MASEF, last September, when lead author Mazen Noureddin joined the Surfers to discuss his recent breakthrough paper on this new NIT. Th...
10 Mar 202413min
S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up
Send us Fan Mail After some final discussion about GLP-1s, this conversation entails Roger Green summarizing what he has heard in the episode so far and testing for confirmation or correction. It goes...
10 Mar 202411min
S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s
Send us Fan Mail This conversation touches on two important subjects: the impact of different potential resmetirom prices on the size and structure of the treatable MASH population, and the impact GLP...
10 Mar 202411min
S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
Send us Fan Mail This conversation focuses more tightly on the specific challenges with the current approaches that use NITs to diagnose and stage advanced MASH fibrosis and explores several newer opt...
10 Mar 202414min
S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients
Send us Fan Mail This conversation explores the challenges with using the current non-invasive tests (NITs) to diagnose patients with F2/F3 advanced MASH fibrosis. If tests today cannot achieve the re...
10 Mar 202412min
S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening
Send us Fan Mail This conversation explores why proper use of non-invasive tests (NITs) will play a pivotal role in increasing the number of patients diagnosed and treated for MASH. It becomes particu...
10 Mar 20248min
S5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024
Send us Fan Mail In 2024, the two major areas for change in diagnosing and treating MASH are new drug approval and changes in use of NITs. Naim Alkhouri and Ian Rowe join Jörn Schattenberg, Louise Ca...
7 Mar 202457min
